Rivermark Medical
Rivermark Medical, an organization devoted to growing a novel therapeutic system for benign prostatic hyperplasia (BPH), introduced right this moment the profitable completion of its RAPID-UR research, an prolonged indication research that evaluated using the Firm’s FloStent System in sufferers struggling urinary retention resulting from BPH. The pilot research included 11 sufferers, and procedures had been carried out by Drs. Ingrid Perscky and Ruben Urena on the Pacifica Salud Costa del Este Hospital in Panama Metropolis, Panama.
Urinary Retention
Urinary retention (UR) refers to a affected person’s incapability to cross urine, typically requiring placement of a short lived indwelling catheter for reduction. BPH is the main reason behind obstructive UR, ensuing from the enlargement of the prostate which restricts and obstructs the movement of urine. Between 53-65% of acute UR circumstances are the results of BPH1,2, and sufferers who’ve skilled acute UR are at a 56% elevated threat for future episodes2. At present, no catheter-free system remedies for UR are commercially out there.
“Urinary retention could be a painful and extreme situation for males with BPH,” acknowledged Adam Kadlec, M.D., Co-Founder and CEO of Rivermark Medical, and training Urologist at Aurora Healthcare in Milwaukee, Wisconsin. “Surgical procedure is commonly really useful, however that is daunting for sufferers and poses important dangers. A constantly efficient, outpatient based mostly, minimally invasive system possibility for sufferers affected by urinary retention is sorely wanted. We’re assured this expanded utility of the FloStent System will tackle this vital unmet want.”
FloStent System
Rivermark’s FloStent System is a uniquely engineered nitinol stent that lightly holds the prostatic urethra to revive regular urinary movement and supply speedy reduction for sufferers with BPH. The system might be deployed throughout an outpatient process utilizing any versatile cystoscope, providing a therapeutic intervention on the time of analysis with fewer problems and minimal restoration time.
Medical Program
Rivermark’s medical program contains just lately finishing the 12-month follow-up for the RAPID-I first-in-human (FIH) medical research, during which sufferers with BPH had been handled utilizing the FloStent System in Panama Metropolis, Panama. Medical knowledge from the RAPID-I FIH research, together with outcomes from the expanded indication research, RAPID-UR, shall be offered at upcoming Urology congresses.
Trending Merchandise
